News

EnGeneIC Honored with 2026 Breakthrough in Glioblastoma Biotech Award at Northwell Foundation Lenox Hill Neurosurgery Brain Cancer Gala in New York

EnGeneIC Doses First Patient with Novel EGFR-Targeted Nanocell Therapy for Recurrent Glioblastoma

EnGeneIC launches groundbreaking new Australian trial for innovative cancer therapy, with international trial site in Singapore to follow

September 24, 2024

EnGeneIC selects global CDMO BioCina to advance their groundbreaking cancer treatment

December 7, 2023

EnGeneIC granted FDA Fast-Track Designation for Novel Armed Nanocell Drug Conjugate Pancreatic Cancer Therapeutic.

November 26, 2023

EnGeneIC’s promising results in 17 pancreatic ductal adenocarcinoma patients clinical trial published in Clinical Cancer Research.

November 8, 2023

EnGeneIC’s advanced metastatic pancreatic ductal adenocarcinoma patient shows no evidence of disease after EDV treatment.

January 31, 2023

EnGeneIC publishes the COVID-EDV vaccine’s novel mechanism of action in a leading Immunology journal.

October 14, 2022

EnGeneIC has won the 2022 Australian Financial Review BOSS Prestigious Award for the most Innovative company in Healthcare (Australia and New Zealand)

Channel 9 News – 27th July 2022

September 07, 2021

EnGeneIC develops world-first nanocellular anti-COVID-19 vaccine that defeats mutant viruses and stimulates a broad anti-viral response

EnGeneIC Announces Board Appointment – Professor Bryan Williams

February 23, 2021

Worldwide Business – kathy ireland interviews Jennifer MacDiarmid

August 11, 2020

EnGeneIC Announces Board Appointment – Dr. Mark Levitt

Abstract accepted to the Annual Meeting of the American Society of Clinical Oncology 2020

Publication in prestigious scientific journal, Cancer Cell, highlighting the ability of EDV™ Nanocells to mount dual assault on Cancer Cells